TY - JOUR
T1 - Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus-I-negative Donors for Adult T-Cell Leukemia/Lymphoma
T2 - Retrospective Analysis of Data from the Japan Marrow Donor Program
AU - Kato, Koji
AU - Kanda, Yoshinobu
AU - Eto, Tetsuya
AU - Muta, Tsuyoshi
AU - Gondo, Hisashi
AU - Taniguchi, Shuichi
AU - Shibuya, Tsunefumi
AU - Utsunomiya, Atae
AU - Kawase, Takakazu
AU - Kato, Shunichi
AU - Morishima, Yasuo
AU - Kodera, Yoshihisa
AU - Harada, Mine
PY - 2007/1
Y1 - 2007/1
N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-matched related donor has been suggested to improve the poor prognosis of adult T-cell leukemia/lymphoma (ATLL). However, the infusion of HTLV-I-infected cells from HTLV-I-positive related donors could lead to the development of donor-derived ATLL under immunosuppressive conditions. Although most ATLL patients lack a suitable HLA-matched related donor and require an HTLV-I-negative unrelated donor, little information is currently available regarding the outcome of unrelated bone marrow transplantation (UBMT) for ATLL. To evaluate the role of UBMT in treating ATLL, we retrospectively analyzed data from 33 patients with ATLL treated by UBMT through the Japan Marrow Donor Program (JMDP). Overall survival (OS), progression-free survival, and cumulative incidence of disease progression and progression-free mortality at 1 year after UBMT were 49.5%, 49.2%, 18.6%, and 32.3%, respectively. Multivariate analysis identified recipient age as an independent prognostic factor for OS (P = .044). Patients age ≥50 years who showed nonremission at transplantation tended to have higher rates of treatment-related mortality. Our observations suggest that UBMT could represent a feasible treatment option for ATLL patients and warrant further investigation based on these risk factors.
AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-matched related donor has been suggested to improve the poor prognosis of adult T-cell leukemia/lymphoma (ATLL). However, the infusion of HTLV-I-infected cells from HTLV-I-positive related donors could lead to the development of donor-derived ATLL under immunosuppressive conditions. Although most ATLL patients lack a suitable HLA-matched related donor and require an HTLV-I-negative unrelated donor, little information is currently available regarding the outcome of unrelated bone marrow transplantation (UBMT) for ATLL. To evaluate the role of UBMT in treating ATLL, we retrospectively analyzed data from 33 patients with ATLL treated by UBMT through the Japan Marrow Donor Program (JMDP). Overall survival (OS), progression-free survival, and cumulative incidence of disease progression and progression-free mortality at 1 year after UBMT were 49.5%, 49.2%, 18.6%, and 32.3%, respectively. Multivariate analysis identified recipient age as an independent prognostic factor for OS (P = .044). Patients age ≥50 years who showed nonremission at transplantation tended to have higher rates of treatment-related mortality. Our observations suggest that UBMT could represent a feasible treatment option for ATLL patients and warrant further investigation based on these risk factors.
UR - http://www.scopus.com/inward/record.url?scp=33845975998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845975998&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2006.09.002
DO - 10.1016/j.bbmt.2006.09.002
M3 - Article
C2 - 17222757
AN - SCOPUS:33845975998
SN - 1083-8791
VL - 13
SP - 90
EP - 99
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 1
ER -